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Background—Despite interest in using electronic health record (EHR) data to assess quality of care, the accuracy of such 
data is largely unknown. We sought to develop and validate transient ischemic attack and minor ischemic stroke electronic 
quality measures (eQMs) using EHR data.
Methods and Results—A random sample of patients with transient ischemic attack or minor ischemic stroke, cared for in 
Veterans Health Administration facilities (fiscal year 2011), was identified. We constructed 31 eQMs based on existing 
quality measures. Chart review was the criterion standard for validating the eQMs. To evaluate eQMs in terms of eligibility, 
we calculated the proportion of patients who were genuinely not eligible to receive a process (based on chart review) and 
who were correctly identified as not eligible by the EHR data (specificity). To assess eQMs about classification of whether 
patients received a process, we calculated the proportion of patients who actually received the process (based on chart 
review) and who were classified correctly by the EHR data as passing (sensitivity). Seven hundred sixty-three patients 
were included. About eligibility, specificity varied from 25% (brain imaging; carotid imaging) to 99% (anticoagulation 
quality). About pass rates, sensitivity varied from 30% (antihypertensive class) to 100% (coronary risk assessment; 
international normalized ratio  measured). The 16 eQMs with ≥70% specificity in eligibility and ≥70% sensitivity in 
pass rates included coronary risk assessment, international normalized ratio measured, HbA1c measurement, speech 
language pathology consultation, anticoagulation for atrial fibrillation, discharge on statin, lipid management, neurology 
consultation, Holter, deep vein thrombosis prophylaxis, oral hypoglycemic intensification, cholesterol medication 
intensification, antihypertensive intensification, antihypertensive class, carotid stenosis intervention, and substance abuse 
referral for alcohol.
Conclusions—It is feasible to construct valid eQMs for processes of transient ischemic attack and minor ischemic stroke 
care. Healthcare systems with EHRs should consider using electronic data to evaluate care for their patients with transient 
ischemic attack and to complement and expand quality measurement programs currently focused on patients with 
stroke.  (Circ Cardiovasc Qual Outcomes. 2017;10:e003157. DOI: 10.1161/CIRCOUTCOMES.116.003157.)
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There has been a call for using electronic health record (EHR) data instead of manual chart review to assess con-
dition-specific quality of care for both processes of care and 
outcomes.1–6 The Centers for Medicare and Medicaid Services 
(CMS) has proposed widespread adoption of electronic qual-
ity measures (eQMs) based on EHR data.7 The articulated 
challenge for the next generation of clinical performance 
measures is to assess quality of care for an entire population 
longitudinally as opposed to conducting chart reviews on a 
sample of patients at single points in time.4
See Editorial by Adelman and Burke
The American Heart Association/American Stroke 
Association (AHA/ASA) has proposed a set of process 
measures for use in evaluating quality of care for patients 
with acute ischemic stroke and transient ischemic attack 
(TIA).8 Similar measures have been supported by the Joint 
Commission (JC) and the National Quality Forum.9,10 The 
JC stroke measures are part of the CMS Hospital Inpatient 
Quality Reporting Program.7 Yet, the evaluation of stroke 
care quality focused on processes of care has historically 
relied on chart review. Although some investigators have 
examined the challenges in constructing certain ischemic 
stroke quality measures from EHR data,11 this study has 
not included all harmonized stroke quality measures or the 
processes of care that have been associated with improved 
outcomes for patients with TIA.12–14
The Veterans Health Administration (VHA) currently 
tracks 3 self-reported hospital-based measures of ischemic 
stroke care quality and previously implemented measurement 
of the JC stroke metrics based on chart review data.15 The VHA 
does not currently assess quality of care for patients with TIA. 
Although patients with TIA and minor ischemic stroke are at 
high risk of recurrent vascular events, evidence demonstrates 
that timely delivery of guideline concordant care dramati-
cally reduces this risk.16–20 By measuring care quality for all 
patients with TIA and minor ischemic stroke, providers can 
help ensure that patients receive the care they need to prevent 
recurrent vascular events.
We sought to develop and validate eQMs that could be 
assessed for patients with TIA and minor ischemic stroke 
using readily available EHR data and that could be used for 
the evaluation of care at the facility level. Specifically, we 
were interested in evaluating guideline-concordant care pro-
cesses that could serve as targets for future quality improve-
ment efforts.
Methods
Terminology: EHR Versus Chart Review Data
The VHA has a robust electronic medical record system which 
is known as the Computerized Patient Record System and which 
is based on the VistA (Veterans Health Information Systems and 
Technology Architecture) platform. Many data elements (eg, vi-
tal signs, laboratory information, and medication information) are 
available within existing VHA data sources that are not generally 
available in administrative data for other health systems. In this 
project, EHR data refer to data elements that are routinely avail-
able for patients in the VHA through existing VHA data sources, 
whereas chart review data refer to information that is collected 
by human abstracters reading medical records. Information that 
is stored in text fields (either free text or templated text) are not 
routinely available in existing VHA EHR databases and thus were 
not included in the development of these TIA or minor ischemic 
stroke eQMs.
Rationale for Focus on TIA and Minor Ischemic 
Stroke
The rationale for including both patients with TIA and those with mi-
nor ischemic stroke in this project was based on 4 elements: approxi-
mately one third of patients with transient neurological symptoms 
who would have been classified according to the traditional time-
based definition of TIA have evidence of infarct on brain imaging 
and would therefore be classified as having a minor ischemic stroke 
according to the tissue-based definition of TIA21; numerous studies 
have examined prognosis after TIA and minor ischemic stroke and 
found that both groups are at high and similar risk of recurrent vas-
cular events20,22,23; several intervention studies have included patients 
with both TIA and minor ischemic stroke17,24; and the AHA/ASA pre-
vention guidelines provide similar recommendations for patients with 
TIA and minor ischemic stroke.25
Overall Design
We used International Classification of Diseases-Ninth Revision 
(ICD-9)-CM codes to identify patients with TIA or minor ischemic 
stroke who were cared for in any VHA Emergency Department 
(ED) or inpatient setting during fiscal year (FY) 2011 (see Cohort 
Construction section of this article). We then identified a random sam-
ple of patients from the 45 facilities with the highest patient volume 
WHAT IS KNOWN
• Despite interest in using electronic health record 
instead of manual chart review to assess condition-
specific quality of care both for processes of care and 
for outcomes, the accuracy of using such data for the 
assessment of stroke and transient ischemic attack 
care are largely unknown.
• Previous studies have, in general, been less explicit 
about issues related to eligibility for a process and 
have focused primarily on agreement in whether the 
measure was passed.
WHAT THE STUDY ADDS
• To our knowledge, this is the first study to assess the 
feasibility of measuring quality of care for patients 
with transient ischemic attack or minor stroke using 
existing electronic health record data.
• A key methodological advance to the existing elec-
tronic quality measurement literature is the detailed 
examination of how electronic quality measures 
compared with the criterion chart review separately 
for issues related to eligibility for a given process 
and the pass rate for that process.
• This study examined a large set of performance 
measures that included a broad array of clinical pro-
cesses of care for patients with transient ischemic 
attack and minor stroke and demonstrated that it is 
feasible to construct valid electronic quality mea-
sures for key processes of acute transient ischemic 
attack and minor stroke care.
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and selected a 35% random sample with a minimum of 25 patients 
per site. We focused on high-volume facilities so that we could evalu-
ate the use of the eQMs at the facility level. Patients were excluded 
if chart review did not confirm a TIA or ischemic stroke diagnosis, if 
the time from symptom onset to presentation was >30 days, or if they 
did not have a mild stroke (defined as an National Institute of Health 
Stroke Scale [NIHSS] score of26 <3). The chart review data served as 
the criterion standard for validity testing of the eQMs.
Cohort Construction
Our goal was to identify all patients with TIA or minor ischemic 
stroke who were cared for in either the ED or inpatient setting. The 
cohort was constructed in 5 steps. First, we identified Veterans with 
TIA or ischemic stroke (minor or major) who were cared for in any 
VHA ED or inpatient setting during FY 2011 (October 2010 to 
September 2011) using the ICD-9 codes of 435.X, 433.X1, 434.00, 
434.X1, and 436.27 We used the diagnosis codes for the inpatient pe-
riod for patients who were admitted and used ED diagnosis codes for 
patients cared for only in the ED. The earliest event date in FY 2011 
was used as the index event.
Second, we classified patients with ischemic stroke as either ma-
jor or minor. Because the EHR data for patients in FY 2011 did not 
include the NIHSS or other measure of stroke severity (in contrast 
to the medical records from which a retrospective NIHSS could be 
obtained), an approach to identifying patients with minor ischemic 
stroke was developed.28 Briefly, the algorithm for the differentiation 
of patients with minor versus major ischemic stroke was developed 
using data from the VHA Office of Quality and Performance (OQP) 
Stroke Special Project, which included detailed chart review on 3965 
patients with ischemic stroke who were hospitalized in any VHA 
medical center in FY 2007.27 Nurse abstractors trained in the col-
lection of the retrospective NIHSS conducted the chart reviews and 
documented the NIHSS on the basis of the admission neurological 
examination.26 Minor stroke (defined as an NIHSS ≤2) was present 
in 1925 (48.5%) and major stroke was present in 2040 (51.5%) pa-
tients in this chart review cohort. EHR data were linked with the chart 
review data. Our study team iteratively developed 17 EHR data algo-
rithms on the basis of a priori clinical judgment to identify patients 
with minor stroke. We calculated the sensitivity and specificity for 
each algorithm. The algorithm with the best performance had a sen-
sitivity of 47.4%, specificity of 78.3%, and correctly classified ≈60% 
of patients as having a minor versus a major stroke. According to this 
algorithm, patients discharged with a diagnosis of stroke were classi-
fied as having major stroke if any of the following were present: the 
length of stay was ≥6 days, ventilator use, feeding tube use, coma, 
intensive care unit stay, received inpatient rehabilitation services, or 
receipt of thrombolysis on the day of presentation. Major stroke pa-
tients were excluded.
Third, we used the EHR data (based on the algorithm described 
above) to identify patients with TIA and minor stroke for chart re-
view. Medical records were screened for 1624 patients, 822 were 
considered eligible for full chart abstraction (defined as a patient with 
a probable TIA or stroke, where the symptom onset was within 30 
days of presentation and where the stroke was minor [NIHSS ≤2]). 
Among the 802 patients who were not eligible for full abstraction the 
reasons for exclusion (not mutually exclusive) included NIHSS >2 
(n=429), not considered as a TIA or stroke by the admitting clinical 
team (n=336), other (n=30) (eg, acute care performed at non-VHA 
facility and being referred to the VHA facility for rehabilitation care 
only or for carotid stenosis procedure; recent completed evaluation of 
cerebrovascular symptoms in patient with likely alternative diagnosis 
for current symptoms such as dehydration or infection; or alterna-
tive explanation for neurological symptoms such as Dilantin toxicity, 
neuropathy, Bell’s palsy, or metastatic cancer), and symptom onset 
earlier than 30 days before presentation (n=16).
Fourth, on the basis of the chart review information, we refined 
the EHR algorithm. We excluded the following: patients with an ICD-
9 code 435.2 (subclavian steal syndrome) because none were found 
to have either a TIA or minor ischemic stroke index event; patients 
who only had a consultation by an emergency medicine provider but 
who were not actually cared for in the emergency department setting; 
non-Veteran patients (eg, family members or staff who had a TIA or 
minor stroke but who did not get their regular care from the VHA 
facility), patients cared for in an ED with a code for TIA or stroke but 
who were admitted within 1 day for a noncerebrovascular diagnosis 
(because on chart review nearly all of these patients actually had a 
noncerebrovascular problem and not a TIA or minor stroke), and pa-
tients where the death date was before the presentation date.
Finally, we identified a random sample of patients (n=763) 
from the 45 facilities with the highest patient volume and selected 
a 35% random sample with a minimum of 25 patients per site. 
These patients then received a full chart review and were included 
in this study.
Chart Review: Interobserver Reliability
To assess inter-rater reliability, our goal was to conduct double ab-
straction on a 10% random sample of records. Because we did not 
have an a priori sense of the proportion of charts that would be ineli-
gible for inclusion in the chart review, we began by identifying 20% of 
records for double abstraction and then decreased that proportion after 
the first year of abstraction. Agreement between chart reviewers for 
categorical variables was measured by percent agreement and by the 
κ statistic, which is agreement adjusted for random chance; κ’s were 
interpreted using Landis and Koch benchmarks.29 The κ is influenced 
by prevalence, with reductions in κ observed when the prevalence is 
either very low or very high.30 The latter situation is relevant to the cur-
rent study given that we anticipated high pass rates for certain process-
es of care (eg, we expected that almost all patients would receive brain 
imaging); for this reason, we used both agreement and κ to quantify 
interobserver reliability. The strength of interobserver reliability in 
continuous variables was measured by the intraclass correlation co-
efficient (ICC), which describes the proportion of total variation in 
observations that is because of subject-to-subject variability in the true 
value. Higher levels of random error associated with the measurement 
process result in lower ICC values; 1–ICC is the proportion of total 
variation from different measurements of the same subject (ie, varia-
tion arising from different chart reviewers). An ICC of 1.0 indicates 
that there was no difference within a subject between chart reviewers.
eQM Development
Process measures were identified from several different sources in-
cluding: AHA/ASA stroke guideline recommended elements of care 
for patients with TIA or ischemic stroke,25 the 2014 Evidence-Based 
Guideline for the Management of High Blood Pressure in Adults,31 
measures currently being used in VHA quality assessment (eg, for 
primary care quality assessment), measures included in the JC Stroke 
Core Measure Set,15 or measures that were part of the proposed AHA/
ASA quality metrics.8,32 EQMs were developed for 31 processes of 
care which spanned 15 domains of care (Table 1): (1) brain imag-
ing; (2) carotid artery imaging and timely carotid stenosis interven-
tion; (3) cardiac monitoring with electrocardiography, telemetry, or 
Holter; (4) hypertension control, antihypertensive medication class, 
and antihypertensive medication intensification; (5) anticoagulation 
for atrial fibrillation or atrial flutter, international normalized ratio 
(INR) measured, and anticoagulation quality (INR between 2 and 
3); (6) lipid measurement, prescription of lipid-lowering agents or 
statins at discharge, prescription of moderate or high potency statin 
at discharge, and lipid-lowering medication intensification; (7) dia-
betes mellitus management with HbA1c measurement and oral hy-
poglycemic medication intensification; (8) antithrombotics by day 
2 and discharge; (9) deep vein thrombosis prophylaxis (with or 
without exclusion of patients who were ambulatory); (10) neurology 
consultation; (11) rehabilitation consultation; (12) speech language 
pathology consultation; (13) nicotine replacement therapy for smok-
ers; (14) substance abuse treatment referral for alcohol abuse; and 
(15) coronary risk assessment. Appendix I in the Data Supplement 
includes definitions for each process of care. Process-measure algo-
rithms were developed for use with VHA administrative data and 
were iteratively refined on the basis of comparisons with the chart 
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review data (Appendix II in the Data Supplement provides an ex-
ample algorithm for the carotid imaging process).
eQM Data Sources
A variety of data sources were used to construct the eQMs. VHA 
Austin inpatient and outpatient data files in the 5 years pre-event (FY 
2005–2012) were used to identify past medical history,33 healthcare uti-
lization (eg, hospitalizations, office visits), and receipt of procedures 
(eg, brain imaging using Current Procedural Terminology, Healthcare 
Common Procedures Coding System, and ICD-9 procedure codes). 
Pharmacy Benefits Management data were used to identify medica-
tions. Corporate Data Warehouse data were used for vital signs (eg, 
blood pressure), laboratory data (eg, lipids, HbA1c), allergies, orders, 
and consults. Linked VA-CMS data were used to identify comorbidity 
and hospitalizations in non-VHA facilities. VA Fee-Basis Data were 
used to identify inpatient and outpatient utilization and medical history. 
The date of death was obtained from the VA Vital Status File. (Appendix 
II in the Data Supplement provides an example of the specific diagnosis 
and procedure codes that were used in eQM development).
eQM Validation
We assessed the validity of the eQMs by comparing the eQMs con-
structed from EHR data to the same QMs constructed from chart re-
view data (criterion standard). The validity of the eQMs was tested 
first for eligibility (the denominators of the eQM) and then separately 
for the pass rate (the numerators of the eQM). The Figure displays the 
2-by-2 tables that were used to conceptualize the validation analysis.
Table 1. Electronic Quality Measures
Clinical Domain  Alternatives to AHA/ASA Measures Secondary Measures
 Core AHA/ASA Measures for Stroke and TIA*
Antithrombotics Antithrombotics at discharge  
Antithrombotics by hospital day 2
Atrial fibrillation Anticoagulation for atrial fibrillation/flutter INR measured Anticoagulation quality
Hyperlipidemia Statin at discharge Lipid management Lipid measurement
Cholesterol-lowering intensification
Smoking  Nicotine replacement therapy for smokers†  
Carotid stenosis Carotid artery imaging  Carotid stenosis management
Hypertension   Hypertension medication intensification
Hypertension control
Antihypertensive medication class
 Core AHA/ASA Measures for Stroke*
DVT prophylaxis DVT prophylaxis  DVT prophylaxis (ambulatory excluded)
Rehabilitation Rehabilitation needs assessment   
Dysphagia Dysphagia screening Speech language pathology consultation  
Dysphagia management
Cardiac monitoring  Electrocardiography  
Telemetry
Holter monitor
Diabetes mellitus   HBA1c measurement
Hypoglycemic medication intensification (oral 
medications)
Hypoglycemic medication intensification 
(insulin)
Brain imaging   Brain imaging
Alcohol abuse   Substance abuse treatment referral for alcohol 
use
Neurology   Neurology consultation
Coronary risk   Coronary risk assessment
AHA/ASA indicates American Heart Association/American Stroke Association; DVT, deep vein thrombosis; INR, international normalized ratio; and TIA, transient 
ischemic attack.
*The AHA/ASA performance measure set for hospitalized patient with ischemic stroke included thrombolytic therapy, time to intravenous thrombolysis, stroke 
education, and National Institute of Health Stroke Scale assessment, which were not included in the current study because they are either less relevant for the TIA/minor 
ischemic stroke population or could not be reliably converted into an electronic quality measure.
†The AHA/ASA performance measure set includes tobacco use counseling which could not be reliably abstracted from electronic health record data; therefore we 
developed the alternative measure related to the prescription of nicotine replacement therapy for tobacco smokers.
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Eligibility Validation
Implementation of quality measures in practice requires both the inclu-
sion of all eligible patients and the exclusion of patients who are not 
eligible. However, to be acceptable to clinicians who are subject to 
quality assessment, inclusion of patients who are not actually eligible 
for a given process must be avoided as clinicians are likely to reject 
measures wholesale if patients who were not eligible for a process, and 
who therefore appropriately did not receive a process are classified as 
a fail when they should have been classified as not eligible. Therefore, 
for the assessment of how well the EHR data performed in terms of 
classifying eligibility for each process of care, we calculated the pro-
portion of patients who were genuinely not eligible to receive a process 
(based on chart review information) and who were correctly identified 
as being not eligible on the basis of the EHR data (specificity; Figure).
Passing Validation
Implementation of quality metrics in practice requires avoiding the 
situation where a quality measure classifies a patient as a fail when 
the clinician actually provided care and therefore the patient should 
really be classified as a pass. Therefore, for the assessment of how 
well the EHR data performed in terms of classifying whether a patient 
received a process of care, we calculated the proportion of patients 
who actually received the process (on the basis of the chart review) 
and who were classified correctly by the EHR as passing the measure 
(sensitivity; Figure). We conducted this assessment among the pa-
tients who were identified as being eligible for a process in both the 
EHR cohort and chart review cohort.
In addition to sensitivity and specificity, positive and negative pre-
dictive values were also calculated. Accuracy was calculated as the 
sum of the true-positives (TP) and true-negatives (TN) over the sum 
of TP, false-positives [FP], TN, and false-negatives [FN]).34 Finally, 
Matthew correlation coefficient (MCC) was calculated for each eQM 
according to the formula: MCC=[(TP*TN)–(FP*FN)]/[((TP+FP)*(T
P+FN)*(TN+FP)*(TN+FN))0.5].35 The MCC describes agreement be-
tween 2 classification systems: in this case, between the electronic data 
and the chart review data. An MCC of 1 indicates perfect agreement, 
0 indicates a random guess, and −1 indicates perfect disagreement. If 
an eQM had high sensitivity and high specificity, then the MCC would 
approach 1. If an eQM had high specificity and low sensitivity or high 
sensitivity and low specificity, then the MCC would be intermediate.
Facility-level pass rates were calculated as the number of patients 
who passed a measure divided by all of the patients treated at that 
facility who were eligible for a measure. Facility pass rates for each 
process of care were examined for facilities with at least 10 eligi-
ble patients (where eligibility was determined on the basis of chart 
review).
This project received human subjects approvals from the 
Institutional Review Board and VHA Research and Development 
Committees.
Results
Cohort Construction and Validation
A total of 763 patients were included in the cohort. The patient 
volume varied across the n=45 facilities from 54 patients to 
218 patients with a mean volume of 98 patients.
All patients were considered as having a possible TIA 
or minor ischemic stroke at the time of presentation and 
therefore clinically eligible to receive care for patients with 
presumed TIA or minor ischemic stroke. Based on chart 
review data, they were classified as having a final diagno-
sis of: TIA (n=502; 65.8%), minor ischemic stroke (n=253; 
33.2%), or as neither TIA nor minor ischemic stroke (n=8; 
1.1%). There was agreement between the EHR data and 
the chart review in terms of overall diagnostic classifica-
tion as either TIA or minor ischemic stroke versus not 
TIA or minor ischemic stroke in 755 of 763 cases (99.0%; 
Table 2).
The characteristics of the cohort are provided in Table 3. 
Although the EHR data identified more comorbid conditions 
than the chart review, the Charlson comorbidity score was 1 
point higher in the chart review cohort. The chart review data 
provided information about the clinical uncertainty inherent 
in making a TIA diagnosis, especially differences in the ini-
tial diagnosis (made in the ED or on admission) versus the 
final diagnosis (made at the end of the index presentation; 
Table 3).
Table 2. Diagnostic Agreement Between Chart Review and 











234 66 4 304 (39.8%)
TIA 19 436 4 459 (60.2%)
Total 253 (33.2%) 502 (65.8%) 8 (1.0%) 763 (100%)
755 (99.0%) 8 (1.0%)
TIA indicates transient ischemic attack.
Figure. Conceptualization of validity 
assessment. EHR indicates electronic 
health record; FP, false-positives; FN, 
false-negatives; TP, true-positives; and 
TN, true-negatives.
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Chart Review: Interobserver Reliability
Double abstraction was performed on a 17% (n=131) random 
sample of medical records. Among the 136 categorical vari-
ables involved in the process-measure definitions, the agree-
ment between chart reviewers was 100% for 41% (n=56) of 
variables, 90% to 99% for 46% (n=62) of variables, 80% to 
89% for 12% (n=17) of variables, and <80% for 1% (n=1) of 
variables. κ's were calculated with 75% of variables having sub-
stantial (33%; 0.60<κ≤0.80) or perfect (42%; 0.80<κ) agree-
ment. Another 12% had moderate (0.40<κ<0.60) agreement, 
9% had fair or slight (0.20<κ≤0.40) agreement, and 4% had 
poor agreement. Among the 28 continuous variables involved 
in the process-measure definitions, the ICC was 1.00 for 61%, 
0.90 to 0.99 for 21%, 0.80 to 0.89 for 7%, and <0.80 for 11%.
eQM Validation: Eligibility Assessment
For the 31 eQMs, the comparison of the EHR data and the 
criterion chart review data for eligibility for each process 
is provided in Table 4. The eQMs are ranked by specificity 
(*). The eQMs with specificity <70% are  identified by the 
label ELT70 (Table 4). The specificity of the eligibility for 
the eQMs varied from a low of 25.0% for brain imaging and 
carotid imaging to a high of 98.6% for anticoagulation quality.
eQM Validation: Pass Rate Assessment
Table 5 provides the comparison of the EHR data and the 
criterion chart review data for the pass rates for the 31 eQMs 
that are ranked by sensitivity (*). Table 5 indicates which 
eQMs had a specificity <70% for eligibility (from Table 4) 
by the label ELT70; eQMs with <70% sensitivity for the 
Index event 
  Final diagnosis  
   TIA 459 60.2 502 65.8 0.0226
   Minor ischemic stroke 304 39.8 253 33.2 …
   Not stroke or TIA … … 8 1.1 …
  Symptoms at time of 
presentation
… … 375 49.1 …
  ABCD2 score, range, 
median
… … 0–7, 4 …
   Mean±SD … … 4.0±1.5 …
  NIHSS score,* range, 
median
… … 0–18, 0 …
   Mean±SD … … 1.0±1.5 …
ABCD2 refers to a measure of recurrent vascular event rate risk; AICD, 
automatic implantable cardioverter-defibrillator; CABG, coronary artery bypass 
grafting; COPD, chronic obstructive pulmonary disease; NIHSS, National Institute 
of Health Stroke Scale; PCI, percutaneous coronary intervention;  and TIA, 
transient ischemic attack.
*The NIHSS was recorded for patients with either TIA or minor ischemic stroke 
and was based on the first physical examination documented upon presentation. 
If a patient with stroke had an NIHSS of >2, they were excluded from the chart 
review. However, patients with TIA were not excluded on the basis of the NIHSS. 
Table 3. Comparison of Baseline Characteristics Between 






P Valuen=763 % n=763 %
Demographics 
  Age, y, range, median 30–94, 66 30–94, 65 …
   Mean±SD 68.1±11.3 67.6±11.3 0.3876
  Race  
   White 566 74.2 514 67.4 0.0034
   Black 153 20.1 152 19.9 …
   Hispanic 17 2.2 32 4.2 …
   Asian 2 0.3 8 1.1 …
   Native American 3 0.4 3 0.4 …
   Other/unknown 22 2.9 54 7.1 …
  Married 381 49.9 379 49.7 0.9184
  Male sex 718 94.1 716 93.8 0.8297
Past medical history 
  Prior stroke 197 25.8 185 24.3 0.4783
  Prior TIA 168 22.0 123 16.1 0.0034
  History of amaurosis fugax 17 2.2 14 1.8 0.5862
  Prior carotid 
endarterectomy or stent
61 8.0 39 5.1 0.0229
  Diabetes mellitus 311 40.8 290 38.0 0.2712
  Hypertension 624 81.8 628 82.3 0.7896
  Hyperlipidemia 556 72.9 518 67.9 0.0331
  Myocardial infarction 116 15.2 89 11.7 0.0427
  Coronary artery disease/
ischemic heart disease/
CABG/PCI/coronary stent
247 32.4 249 32.6 0.9130
  Pacemaker or AICD 19 2.5 60 7.9 <0.0001
  Peripheral vascular disease 198 26.0 65 8.5 <0.0001
  Atrial fibrillation 87 11.4 85 11.1 0.8714
  Congestive heart failure 183 24.0 77 10.1 <0.0001
  Valvular heart disease: 
native or mechanical
105 13.8 25 3.3 <0.0001
  COPD/asthma 278 36.4 129 16.9 <0.0001
  Sleep apnea 128 16.8 91 11.9 0.0069
  Seizure disorder 52 6.8 27 3.5 0.0039
  Migraine disorder 44 5.8 44 5.8 1.0000
  Dialysis dependent 19 2.5 10 1.3 0.0915
  Dementia 35 4.6 62 8.1 0.0046
  Depression 270 35.4 191 25.0 <0.0001
  Charlson comorbidity 
score, range, median
0–12, 1  0–13, 2 …








P Valuen=763 % n=763 %
7  Bravata et al  Electronic Quality Measures for TIA/Minor Ischemic Stroke 
Table 4. Comparison of Chart Review vs the Administrative Data for Eligibility for Processes of Care (n=763)
Processes Eligible by EHR





(d/[b+d]), %* 95% CI,* % PPV, % NPV, % MCC, % ACC, %
Eligible by Chart Review  
(Criterion Standard) Yes (a) No (b) Yes (c) No (d)
Anticoagulation quality 32 10 9 712 78.05 98.61 97.76–99.46 76.19 98.75 0.7580 0.9751
Oral hypoglycemic medication 
intensification
47 11 11 694 81.03 98.44 97.53–99.35 81.03 98.44 0.7947 0.9712
Carotid stenosis intervention 14 13 1 735 93.33 98.26 97.32–99.20 51.85 99.86 0.6883 0.9817
INR measured 32 14 9 708 78.05 98.06 97.05–99.07 69.57 98.74 0.7210 0.9699
Substance abuse referral for alcohol 26 36 22 679 54.17 94.97 93.37–96.57 41.94 96.86 0.4366 0.924
Speech language pathology consultation 567 10 11 175 98.10 94.59 91.33–97.85 98.27 94.09 0.9252 0.9725
Anticoagulation for atrial fibrillation/flutter 53 40 12 658 81.54 94.27 92.55–95.99 56.99 98.21 0.6469 0.9318
Antihypertensive class among 
hypertensives at discharge
164 34 104 461 61.19 93.13 90.90–95.36 82.83 81.59 0.5916 0.8191
DVT prophylaxis 419 22 26 296 94.16 93.08 90.29–95.87 95.01 91.93 0.8709 0.9371
HBA1c measurement 283 33 14 433 95.29 92.92 90.59–95.25 89.56 96.87 0.8731 0.9384
Coronary risk assessment 157 42 106 458 59.70 91.60 89.17–94.03 78.89 81.21 0.5552 0.806
Antihypertensive intensification 220 66 22 455 90.91 87.33 84.47–90.19 76.92 95.39 0.7522 0.8847
Antihypertensive class among 
hypertensives ≤90 d
137 72 131 423 51.12 85.45 83.34–88.56 65.55 76.35 0.3915 0.7339
Telemetry 463 52 15 233 96.86 81.75 77.27–86.23 89.90 93.95 0.8119 0.9122
Nicotine replacement therapy 133 109 35 486 79.17 81.68 78.57–84.79 54.96 93.28 0.5418 0.8113
Cholesterol medication intensification 408 49 123 183 76.84 78.88 73.63–84.13 89.28 59.80 0.5229 0.7746
Lipid management 513 50 49 151 91.28 75.12 69.14–81.10 91.12 75.50 0.6651 0.8702
Discharged on statin 513 50 49 151 91.28 75.12 69.14–81.10 91.12 75.50 0.6651 0.8702
Holter 642 27 17 77 97.42 74.04 65.61–82.47 95.96 81.91 0.746 0.9423
Neurology consultation 757 0 6 0 99.21 … … 100.00 0.00 … 0.9921
ELT70 Hypertension control (n=608)† 575 9 4 20 99.31 68.97 52.13–85.81 98.46 83.33 0.7473 0.9786
ELT70 High or moderate potency statin at 
discharge
636 43 15 69 97.70 61.61 52.60–70.62 93.67 82.14 0.6705 0.924
ELT70 DVT prophylaxis (ambulatory 
excluded)
76 317 14 356 84.44 52.90 49.13–56.67 19.34 96.22 0.2410 0.5662
ELT70 Antithrombotics at discharge 670 47 11 35 98.38 42.68 31.97–53.39 93.44 76.09 0.5344 0.9240
ELT70 Rehabilitation consultation 708 30 4 21 99.44 41.18 27.67–54.69 95.93 84.00 0.5698 0.9554
ELT70 Antithrombotics by day 2 671 50 9 33 98.68 39.76 29.23–50.29 93.07 78.57 0.5247 0.9227
ELT70 Lipid measurement 712 30 2 19 99.72 38.78 25.14–52.42 95.96 90.48 0.5768 0.9581
ELT70 Antihypertensive medication class at 
discharge
570 109 15 69 97.44 38.76 31.60–45.92 83.95 82.14 0.4891 0.8375
ELT70 Electrocardiography 666 69 4 24 99.40 25.81 16.92–34.70 90.61 85.71 0.4387 0.9043
ELT70 Carotid artery imaging 685 57 2 19 99.71 25.00 15.26–34.74 92.32 90.48 0.4523 0.9227
ELT70 Brain imaging 663 72 4 24 99.40 25.00 16.34–33.66 90.20 85.71 0.4304 0.9004
ACC indicates accuracy (the sum of the true-positives and true-negatives over the sum of true-positives, false-positives, true-negatives, and false-negatives); 
DVT, deep vein thrombosis; EHR, electronic health record; ELT70, processes of care with a specificity of <70% for eligibility; INR, international normalized ratio; 
MCC, Matthew correlation coefficient; NPV, negative predictive value; and PPV, positive predictive value.
*The electronic quality measures are ranked by specificity.
†There were 608 patients with valid blood pressure measurements; for all other processes n=763.
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pass rate are identified by the label PLT70. The sensitivity 
of the pass rates varied from a low of 29.7% for the anti-
hypertensive class among patients with hypertension within 
90 days of the index event to a high of 100.0% for coronary 
risk assessment and for INR measured among patients with 
anticoagulation.
The MCCs in Table 5 were generally higher for processes 
with high sensitivity in terms of the pass rate, but there were 
Table 5. Comparison of Chart Review vs the Administrative Data for Pass Rates for Processes of Care (n=763)
Process
Passing by 
EHR Failing by EHR
Sensitivity 
(a/[a+c]),* % 95% CI,* %
Specificity 
(d/[b+d]), % PPV, % NPV, % MCC ACC






Coronary risk assessment 1 5 0 151 100.00 … 96.79 16.67 100.00 0.4017 0.9682
INR measured 32 0 0 0 100.00 … … 100.00 … … 1.0000
HBA1c measurement 219 14 2 48 99.10 97.85–100.35 77.42 93.99 96.00 0.8298 0.9435
Speech language pathology consultation 123 41 2 401 98.40 96.20–100.60 90.72 75.00 99.50 0.8149 0.9242
ELT70 Lipid measurement 575 48 11 78 98.12 97.02–99.22 61.90 92.30 87.64 0.6927 0.9171
Anticoagulation for atrial fibrillation/flutter 41 5 1 6 97.62 93.01–102.23 54.55 89.13 85.71 0.6248 0.8868
Discharged on statin 420 34 15 44 96.55 94.83–98.27 56.41 92.51 74.58 0.5961 0.9045
Lipid management 427 31 16 39 96.39 94.65–98.13 55.71 93.23 70.91 0.5781 0.9084
ELT70 Hypertension control† (n=608) 378 39 15 143 96.18 94.28–98.08 78.57 90.65 90.51 0.7789 0.9061
ELT70 Brain imaging 629 7 25 2 96.18 94.71–97.65 22.22 98.90 7.41 0.1077 0.9517
ELT70 Antithrombotics by day 2 590 32 27 22 95.62 94.01–97.23 40.74 94.86 44.90 0.3802 0.9121
ELT70 Antithrombotics at discharge 581 39 34 16 94.47 92.66–96.28 29.09 93.71 32.00 0.2461 0.8910
ELT70 Carotid artery imaging 426 50 28 181 93.83 91.62–96.04 78.35 89.50 86.60 0.7412 0.8861
Neurology consultation 529 68 41 119 92.81 90.69–94.93 63.64 88.61 74.38 0.5962 0.856
ELT70 High or moderate potency statin at 
discharge
123 114 10 389 92.48 88.00–96.96 77.34 51.90 97.49 0.5872 0.805
Holter 15 19 2 606 88.24 72.93–103.55 96.96 44.12 99.67 0.6108 0.9673
DVT prophylaxis 309 27 44 39 87.54 84.09–90.99 59.09 91.96 46.99 0.4262 0.8305
Oral hypoglycemic medication intensification 13 6 2 26 86.67 72.63–104.71 81.25 68.42 92.86 0.6451 0.8298
Cholesterol medication intensification 95 25 15 273 86.36 79.95–92.77 91.61 79.17 94.79 0.7594 0.902
Antihypertensive intensification 43 20 7 150 86.00 76.38–95.62 88.24 68.25 95.54 0.6882 0.8773
ELT70 Rehabilitation consultation 289 45 48 326 85.76 82.03–89.49 87.87 86.53 87.17 0.7366 0.8686
ELT70 DVT prophylaxis (ambulatory excluded) 56 2 10 8 84.85 76.20–93.50 80.00 96.55 44.44 0.5156 0.8421
ELT70 Antihypertensive medication class at 
discharge
314 32 84 140 78.89 74.88–82.90 81.40 90.75 62.50 0.5666 0.7965
ELT70 Electrocardiography 433 38 140 55 75.57 72.05–79.09 59.14 91.93 28.21 0.2644 0.7327
Antihypertensive class among hypertensives at 
discharge
88 4 29 43 75.21 67.39–83.03 91.49 95.65 59.72 0.6078 0.7988
Carotid stenosis intervention 3 0 1 10 75.00 32.56–117.44 100.00 100.00 90.91 0.8257 0.9286
Substance abuse referral for alcohol 0 1 0 25 … … 96.15 0.00 100.00 … 0.9615
PLT70 Telemetry 267 14 157 65 62.97 58.37–67.57 82.28 95.02 29.28 0.3316 0.66
PLT70 Nicotine replacement therapy 54 10 39 30 58.06 48.03–68.09 75.00 84.38 43.48 0.3035 0.6316
PLT70 Anticoagulation quality 4 1 3 24 57.14 20.48–93.80 96.00 80.00 88.89 0.6051 0.8750
PLT70 Antihypertensive class among 
hypertensives ≤90 d
22 14 52 49 29.73 19.32–40.14 77.78 61.11 48.51 0.085 0.5182
ACC indicates accuracy (the sum of the true-positives and true-negatives over the sum of true-positives, false-positives, true-negatives, and false-negatives); DVT, 
deep vein thrombosis; EHR, electronic health record; ELT70, processes of care with a specificity of <70% for eligibility (from Table 4); INR, international normalized ratio; 
MCC, Matthew correlation coefficient; NPV, negative predictive value; PLT70, processes of care with a sensitivity of <70% for passing; and PPV, positive predictive value.
*The electronic quality measures are ranked by sensitivity.
†There were 608 patients with valid blood pressure measurements; for all other processes, n=763.
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2 notable exceptions to that rule: brain imaging and carotid 
stenosis intervention. The brain imaging process had a rela-
tively higher sensitivity of 96.2%, but the MCC was only 0.11 
reflected the lower specificity of 22.2%. For 25 patients, the 
chart review indicated that the patients received brain imag-
ing but the EHR data had no evidence of brain imaging (FN), 
and for 7 patients, brain imaging information was found in 
the EHR but not in the chart review (FP). The majority of FN 
were for patients where brain imaging had been performed at 
a community (non-VHA) hospital and where the results were 
documented in the medical record but for whom no VHA 
brain image was performed and therefore no brain imaging 
code was found in the EHR data. In contrast, the carotid ste-
nosis intervention had a lower sensitivity of 75.0%, but the 
MCC was 0.83 and the specificity was 100.0%. These results 
reflected the very small sample size for this measure.
Overall eQM Validation
There were 16 eQMs with ≥70% specificity in eligibility and 
≥70% sensitivity in pass rates including coronary risk assess-
ment, INR measured, HbA1c measurement, speech language 
pathology consultation, anticoagulation for atrial fibrillation, 
discharge on statin, lipid management, neurology consulta-
tion, Holter, deep vein thrombosis prophylaxis, oral hypogly-
cemic intensification, cholesterol medication intensification, 
antihypertensive medication intensification, antihypertensive 
class among hypertensive patients at discharge, carotid ste-
nosis intervention, and substance abuse referral for alcohol. 
Conversely, the 15 eQMs with <70% specificity for eligibil-
ity or sensitivity for the pass rate included lipid measurement, 
hypertension control, brain imaging, antithrombotics by day 
2 or at discharge, carotid artery imaging, high or moderate 
potency statin at discharge, rehabilitation consultation, deep 
vein thrombosis prophylaxis excluding ambulatory patients, 
antihypertensive medication class at discharge, electrocardi-
ography, telemetry, nicotine replacement therapy, anticoagu-
lation quality, and antihypertensive class among hypertensive 
patients within 90 days.
Facility-Level Pass Rates
The mean pass rates at the facility level (for facilities with at 
least 10 eligible patients) varied across the eQMs from a low 
of 3.6% for Holter use to high of 94.8% for INR measured 
among patients on anticoagulation (Table 6). Variation in per-
formance across sites was demonstrated by higher values for 
the interquartile range; for example, the median facility pass 
rate for neurology consultation for facilities with at least 10 
eligible patients was 82.4% and interquartile range of 20.9% 
(Table 6).
Discussion
This study assessed the feasibility of measuring quality of care 
for patients with TIA or minor ischemic stroke using existing 
EHR data. A key methodological advance to the existing elec-
tronic quality measurement literature is the detailed exami-
nation of how eQMs compare with the criterion chart review 
separately for issues related to eligibility for a given process 
and the pass rate for that process. Prior studies have, in gen-
eral, been less explicit about issues related to eligibility for a 
process and have focused primarily on agreement in whether 
the measure was passed.12,13
Dr Linda Williams’ group conducted a key-related study 
in this field, developing 5 eQMs for patients with ischemic 
stroke: deep vein thrombosis prophylaxis, antithrombotics by 
hospital day 2 and at discharge, rehabilitation assessment, and 
documentation of the NIHSS.11 Similar to the approach used 
in the current study, they compared results of queries based on 
the EHR with chart review for patients from 11 VHA hospi-
tals. The current project differs from this previous study gives 
our focus on TIA (rather than stroke), the inclusion of all acute 
care VHA facilities (rather than 11 hospitals participating in 
a quality improvement project), and the evaluation of a broad 
array of processes of care. The current project is similar to this 
previous study in the main finding that individual processes of 
care vary in terms of agreement with the EHR. The 2 studies 
had very similar findings for antithrombotics both at hospital 
day 2 and discharge with high denominator sensitivities but 
with low specificities.11
Because no accepted standard exists for the evaluation of 
eQMs, organizations that seek to implement eQMs will be 
faced with competing priorities on the choice of which eQMs 
to use. At a minimum, the choice involves 3 key domains: the 
clinical importance of a process of care, the availability of 
existing electronic data, and the performance characteristics 
of the eQM compared with a criterion or gold standard (in this 
case, chart review).
For this study, we examined 31 eQMs across 15 domains of 
care. We cannot rank the clinical importance of those domains 
given the heterogeneity in the evidence that links diagnostic 
and therapeutic processes with outcomes for patients with 
cerebrovascular disease.25 For example, we cannot answer the 
question: Which is more important, anticoagulation for atrial 
fibrillation or carotid artery imaging? Organizations that seek 
to implement eQMs need to consider the relative importance 
of a given process when evaluating the eQM validity data. Very 
reasonably, these organizations may opt to include eQMs on 
the basis of the clinical importance of the process rather than 
its performance characteristics when compared with chart 
review. For example, carotid stenosis management is a Class 
I; Level of Evidence A from the AHA/ASA secondary preven-
tion guidelines; therefore, carotid imaging is a key process of 
TIA care.25 The eQM for carotid imaging had relatively high 
sensitivity for pass rate (94%) but low sensitivity for eligi-
bility (25%). Organizations seeking to implement this clini-
cally important eQM should carefully examine denominator 
exclusions: for example, although excluding patients who 
leave against medical advice (AMA) is clinically reasonable, 
the lack of AMA discharge data from the ED setting caused 
irreconcilable differences between the chart review data and 
the EHR data in our cohort. A final consideration related to 
clinical importance of an eQM involves the sample size of the 
eligible patient population at the facility level.
About data quality, EHR systems are likely to have unique 
challenges relevant to both eligibility and pass rates. In gen-
eral, processes with eligibility criteria that were based on 
items that are routinely found in administrative databases (eg, 
diagnosis codes, procedure codes, or discharge disposition) 
had strong performance (eg, carotid stenosis intervention). 
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Similarly, processes with pass rates based on procedures or 
laboratory tests had strong performance (eg, HbA1c measure-
ment). In some cases, we found the results of laboratory tests 
in the EHR data that were not present in the chart review (eg, 
FP for HbA1c, lipid measurement). As described by other 
authors, it may be that the electronic data are more accurate 
than chart review in these situations.12 Generally, for processes 
that relied on orders (eg, telemetry), if we identified the order 
in the EHR, then it was nearly always also present in the chart 
review data. In contrast, processes with tight time constraints 
Table 6. Performance of Electronic Quality Measures at the Facility Level*
Process of Care








No. of Patients per 
Facility
Mean 
Pass Rate Min Max Median IQR
n %† n Min Max Median % % % % %
INR measured 59 94.8 … … … … … … … … …
ELT70 Brain imaging 39 93.1 34 11 43 21 93.4 75 100 95 8.7
ELT70 Antithrombotics at discharge 39 92.8 34 11 43 21 92.0 76.2 100 92.7 12.5
ELT70 Antithrombotics by day 2 39 91.7 34 11 43 21 90.8 75.0 100 91.5 13.0
Lipid management 39 89.2 31 12 43 21 88.1 58.3 100 88.9 13.7
ELT70 Lipid measurement 39 88.5 34 11 43 21 87.9 66.7 100 89.7 11.2
Discharged on statin 39 88.4 31 12 43 21 87.1 58.3 100 88.2 15.2
HBA1c measurement 39 81.3 14 18 43 24.5 80.3 58.3 100 78.5 15
ELT70 DVT prophylaxis (ambulatory excluded) 39 79.1 21 15 43 21 78.9 40 100 88.9 25.6
DVT 39 78.8 24 13 43 21 79.1 40 100 87.3 24.1
Anticoagulation for atrial fibrillation 39 77.6 1 36 36 36 90 90 90 90 0
ELT70 Hypertension control 59 73.9 33 10 46 19 71.9 55 100 70 11.9
Neurology consultation 39 73.6 34 11 43 21 79 38.9 100 82.4 20.9
ELT70 Electrocardiography 39 69.6 34 11 43 21 68.4 13 100 75.4 37.8
ELT70 Carotid artery imaging 39 67.5 34 11 43 21 67.3 34.8 91.7 67.5 17.4
ELT70 Antihypertensive medication class at discharge 39 58.9 32 12 43 21 59.2 33.3 88.2 58.7 14.6
Antihypertensive class among hypertensives at discharge 39 58.3 5 26 43 36 58 36.4 81.8 50 38.3
PLT70 Telemetry 39 53.9 30 13 43 21 54.8 0 100 64.4 54.9
ELT70 Rehabilitation consultation 39 49.0 34 11 43 21 45.7 5.6 71.4 46.9 22.4
Oral hypoglycemic intensification 59 44.8 … … … … … … … … …
PLT70 Nicotine replacement therapy 39 43.1 7 16 43 27 41.6 6.3 75 45.5 54
Antihypertensive intensification 39 36.2 10 16 43 24.5 31.3 0 80 28.2 27.3
ELT70 High or moderate potency statin at discharge 39 34.1 33 12 43 21 35.2 9.5 76.5 31.3 20.4
Cholesterol medication intensification 39 28.6 25 13 43 22 28.7 0 58.3 30.8 18.9
Speech language pathology consultation 39 28.1 32 12 43 21 29.8 0 86.7 27 31
PLT70 Antihypertensive class among hypertensives within 
90 d
59 22.3 2 27 41 34 26.8 23.5 30 26.8 6.5
Carotid stenosis intervention 39 13.0 … … … … … … … … …
PLT70 Anticoagulation quality 59 8.0 … … … … … … … … …
Substance abuse referral for alcohol 39 7.6 … … … … … … … … …
Coronary risk assessment 59 6.6 4 29 41 35 6.6 0 18.2 4.2 13.3
Holter 59 3.6 33 12 41 20 6.1 0 26.7 5.6 7.7
DVT indicates deep vein thrombosis; ELT70, processes of care with a specificity of <70% for eligibility; INR, international normalized ratio; and PLT70, processes of 
care with a sensitivity of <70% for passing.
*Chart review was conducted at 45 facilities. There were n=59 facilities for some measures because for the postdischarge measures, quality of care was attributed 
to the facility that provided primary care to the patient, which may or may not have been the same facility that provided care for the index event.
†The electronic quality measures are ranked according to the mean facility pass rate.
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for eligibility had lower performance (eg, lipid measurement 
with exclusions within 2 days of index event presentation).
For some processes, differences between the EHR data 
and the chart review data are unlikely to be easily rectified, 
whereas with other processes, disagreement may indicate 
gaps in EHR data that could be addressed with modifications 
to current systems. For example, for some processes (eg, 
anticoagulation for atrial fibrillation), patient refusal can be 
a source of disagreement between the EHR and the medical 
record; in such a case, it may be possible to create elements in 
the EHR to identify patient preferences.5
We determined in advance that the key consideration when 
evaluating eligibility would be the proportion of patients who 
were genuinely not eligible to receive a process and who were 
correctly identified as being not eligible on the basis of the 
EHR data (specificity) because implementation of quality 
metrics in practice requires avoiding the inclusion of patients 
who are not eligible for a given process. We also determined in 
advance that the proportion of patients who actually received 
the process and who were classified correctly by the EHR as 
passing the measure (sensitivity) would be the key consider-
ation when evaluating passing validity because implementa-
tion of quality metrics in practice requires minimizing the 
classification of patients as fails when they actually received a 
process. The data provided in Tables 4 and 5 demonstrate that 
other choices could be made to rank eQMs (eg, MCC or accu-
racy) that would produce a different set of measures identified 
as best or even acceptable. These tables illustrate how agree-
ment alone is inadequate as a measure of eQM performance, 
and we recommend that future studies of eQMs report results 
using a variety of test characteristics.
The 16 eQMs with ≥70% specificity in eligibility and 
≥70% sensitivity in pass rates encompassed different domains 
of care: medication therapy (eg, anticoagulation for atrial 
fibrillation), laboratory testing (eg, HbA1c measurement), 
consultation (eg, speech language pathology), diagnostic pro-
cedures (eg, Holter monitoring), and therapeutic procedures 
(eg, carotid stenosis intervention). They also spanned the con-
tinuum of care from the early postevent period (eg, neurol-
ogy consultation) to discharge (eg, discharge on statin) to the 
postdischarge period (eg, INR measured). The evidence from 
1 VHA-based study that quality of care in one part of the care 
continuum (eg, processes provided in the ED) was unrelated 
to care in other parts of the continuum (eg, processes provided 
at discharge or by primary care) within a given facility under-
scores the need to develop quality metrics that describe key 
components of care across the entire continuum of care.36
Several national organizations have called for the mea-
surement of processes of care for patients with acute stroke 
and TIA.8,10,15,37 The increased interest in using electronic data 
instead of chart review for the measurement of quality stems 
from a general emphasis on Meaningful Use, the emergence 
of commercial EHR systems, the need to reduce the consider-
able costs involved in detailed chart review, and the imple-
mentation of the CMS electronic Clinical Quality Measures 
program.3,4 The CMS electronic Clinical Quality Measures 
validation pilot identified a variety of challenges for eQM 
implementation including the need for hospital EHR systems 
to include needed data as searchable data elements (rather than 
free text) and standardization of key data elements.7 A few 
studies have evaluated the validity of using EHR data for the 
assessment of quality and have found that EHR data perform 
well in comparison with chart review, but none of these have 
focused on processes of care within TIA populations.12,13,38
There has been considerable interest in measuring qual-
ity of care for patients with stroke both within and outside of 
the VHA.7,9,28 There seem to be fewer organizations; however, 
actively monitoring quality of care for patients with TIA39 
despite the evidence that providing timely, guideline-concor-
dant care substantially reduces the risk of recurrent vascular 
events.16–19 National organizations such as the AHA/ASA, JC, 
NQF, and CMS may wish to consider implementing quality 
measurement programs that focus specifically on patients 
with TIA. One consideration related to the implementation of 
TIA performance measurement is the diagnostic uncertainty 
inherent in the TIA diagnosis and the related issues of validity 
with TIA coding. In the current study, the primary discrep-
ancy between EHR data and chart review was related to the 
identification of patients with minor (versus major) stroke. 
The NIHSS >2 exclusion was present in 429 of 1624 patients 
(26.4%) in the EHR sample. The next most common reason 
for exclusion was that the patient was not considered as a 
stroke or TIA by the admitting team that was present in 336 of 
1624 patients (20.7%) who were included in the EHR sample. 
The question of how inclusion of such patients in a quality 
reporting system might influence the feasibility or usefulness 
differs for these 2 exclusions. In the case of potentially includ-
ing patients with major stroke in a measurement system that is 
targeting TIA and minor stroke, it is likely that the application 
of the eQMs to patients with major stroke would not compro-
mise acceptance of the measurement system because patients 
with major stroke are generally eligible for all of the processes 
that are recommended for patients with TIA and minor stroke. 
In contrast, including patients who are not considered to have 
a stroke or TIA as the primary presenting clinical problem 
would be problematic for clinical acceptance. Healthcare 
systems must assess the relative value of conducting quality 
measurement among a high-risk group of patients with the 
existing limitations in coding.
For most quality assessment programs, patients are identi-
fied on the basis of discharge diagnosis. This approach has 
strong face validity and is mostly likely to include eligible 
patients. However, for conditions where there is both some 
diagnostic uncertainty early and a need for timeliness in care, 
it may be appropriate to consider applying the quality mea-
surement to the presenting complaint. In the case of TIA, 
certain processes of care are relevant to making a correct diag-
nosis (eg, brain imaging).21
Future research in this field should address issues related 
to implementation of performance measurement for patients 
with TIA and minor stroke. Specifically, future research 
should evaluate clinicians perspectives on the benefits versus 
harms of measurement in a clinical domain where the rela-
tively high risk of adverse events can be substantially reduced 
by timely interventions but the condition has an inherent 
diagnostic uncertainty that makes identification of patients 
difficult. It may be that clinicians would welcome timely and 
actionable data about their patients—which would be feasible 
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using eQMs in healthcare systems with EHRs—as long as the 
eQMs are used for clinical care or local quality improvement 
and not for high-stakes report cards or profiling.
Strengths and Limitations
The strengths of this research include its examination of a large 
set of performance measures that included a broad array of 
clinical domains and its rigor in validating via chart review. For 
example, the validation of the brain imaging and carotid artery 
imaging processes may have value for the assessment of quality 
for patients with major ischemic stroke. An additional strength 
of the study is its focus on VHA data and VHA facilities, as the 
VHA comprises the largest integrated healthcare system in the 
United States. The VHA began implementing electronic quality 
measurement—mostly in primary care—in FY 2015.
The focus on the VHA, however, may also represent a 
study limitation in that eQMs feasible for construction within 
the robust VHA EHR system may be less feasible or valid 
within healthcare systems where administrative (claims) data 
do not include pharmacy, laboratory, and consultation data 
and where Medicare data may not be routinely available. 
Increasingly, however, the results may be generalizable to 
healthcare systems using certified commercial EHR systems 
that do include vital sign, pharmacy, laboratory, and orders 
data.
The algorithms that were validated in this study were based 
on ICD-9 codes and translation to ICD-10 will be required for 
implementation in the current routine practice.
Although a strength of the current project is the inclusion 
of a variety of processes of care, some of those processes may 
be more relevant to patients with stroke than patients with TIA. 
For example, patients with transient neurological symptoms 
are unlikely to require rehabilitation assessment. A limitation 
of EHR data are that it cannot be used to identify patients with 
versus those without residual neurological symptoms. Future 
studies should evaluate the degree to which eQMs for TIA and 
minor stroke are associated with postevent patient outcomes.
After the approach used by the JC, we evaluated (Table 5) 
and reported (Table 6) the proportion of eligible patients 
who receive processes of care,9 rather than constructing risk-
adjusted models.
We assessed the performance of the eQMs in the entire 
population; future studies should evaluate the degree to which 
validity in eligibility and pass rate varies across facilities.
Finally, we conceptualized this project as a comparison of 
eQMs against a criterion standard of chart review. We made 
this choice because the existing standard approach for qual-
ity measurement by the JC and other national organizations 
that monitor quality of care is based on chart review.9,39,40 The 
consequence of this conceptualization is that if an eQM dis-
agreed with chart review, we considered it to have poor valid-
ity. However, for some data fields (eg, laboratory tests), it may 
be that the electronic data were more accurate than the chart 
review data12,13; if so, then we may have underestimated the 
true validity of the eQMs.
Conclusions
These results demonstrate that it is feasible to construct valid 
eQMs for key processes of acute TIA and minor ischemic 
stroke care. Healthcare systems with EHRs should consider 
routinely using electronic data to evaluate care for their patients 
with TIA and to complement and expand quality measurement 
programs currently focused on patients with stroke. The eQMs 
that were validated in this project are being deployed as part of 
a quality improvement project in the VHA system.
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